These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 7612899)

  • 21. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
    Gallagher AP; Burnett AK; Bowen DT; Darley RL
    Cancer Res; 1998 May; 58(9):2029-35. PubMed ID: 9581849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
    Hollestelle A; Elstrodt F; Nagel JH; Kallemeijn WW; Schutte M
    Mol Cancer Res; 2007 Feb; 5(2):195-201. PubMed ID: 17314276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of new anti-cancer peptides from conformational energy analysis of the oncogenic ras-p21 protein and its complexes with target proteins.
    Pincus MR
    Front Biosci; 2004 Sep; 9():3486-509. PubMed ID: 15353372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogenic Ras triggers cell suicide through the activation of a caspase-independent cell death program in human cancer cells.
    Chi S; Kitanaka C; Noguchi K; Mochizuki T; Nagashima Y; Shirouzu M; Fujita H; Yoshida M; Chen W; Asai A; Himeno M; Yokoyama S; Kuchino Y
    Oncogene; 1999 Apr; 18(13):2281-90. PubMed ID: 10327074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
    Donovan CA; Pommier RF; Schillace R; O'Neill S; Muller P; Alabran JL; Hansen JE; Murphy JA; Naik AM; Vetto JT; Pommier SJ
    JAMA Surg; 2013 Sep; 148(9):873-8. PubMed ID: 23884447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ras Signaling in Breast Cancer.
    Moon A
    Adv Exp Med Biol; 2021; 1187():81-101. PubMed ID: 33983574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells.
    Yoo BH; Khan IA; Koomson A; Gowda P; Sasazuki T; Shirasawa S; Gujar S; Rosen KV
    Autophagy; 2018; 14(1):134-151. PubMed ID: 28933585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
    Saisana M; Griffin SM; May FE
    Oncotarget; 2016 Aug; 7(34):54445-54462. PubMed ID: 27437872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis.
    Zhang F; Virshup DM; Cheong JK
    Oncogene; 2018 Jan; 37(3):363-376. PubMed ID: 28945225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
    Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
    Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway.
    Wang L; Zhao Y; Xiong Y; Wang W; Fei Y; Tan C; Liang Z
    Exp Cell Res; 2018 Jan; 362(2):424-435. PubMed ID: 29246726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
    Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
    Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.
    Capella G; Cronauer-Mitra S; Pienado MA; Perucho M
    Environ Health Perspect; 1991 Jun; 93():125-31. PubMed ID: 1685441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis.
    Shannon K
    Curr Opin Hematol; 1995 Jul; 2(4):305-8. PubMed ID: 9372012
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular biology of breast carcinoma.
    el-Ashry D; Lippman ME
    World J Surg; 1994; 18(1):12-20. PubMed ID: 8197767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.